<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949115</url>
  </required_header>
  <id_info>
    <org_study_id>COL00729</org_study_id>
    <nct_id>NCT02949115</nct_id>
  </id_info>
  <brief_title>Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances</brief_title>
  <official_title>Acute and Chronic Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Agriculture (USDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aside from aging, numerous factors increase the risk for developing cardiovascular disease
      (CVD) including diet and nutrition. High-fat meal consumption induces postprandial vascular
      endothelial dysfunction and other cardiometabolic disturbances (e.g. dyslipidemia and
      hyperglycemia) in normal weight individuals and is exacerbated in overweight/obese
      individuals. These postprandial responses are likely largely due to activation of
      pro-inflammatory and pro-oxidant pathways. Given that much of the day is spent in the
      postprandial state, this may further impair cardiovascular health in aging overweight/obese
      individuals. Interventions that attenuate these responses are needed. Red beetroot (Beta
      vulgaris L.) is an excellent source of bioactive compounds including nitrate, flavonoids,
      phenolic acids, betalains, carotenoids, and ascorbic acid. These bioactive compounds and
      their metabolites have been shown to have antioxidative, anti-inflammatory, and
      cardiovascular-protective effects. These effects, particularly the cardiovascular-protective
      effects, have been primarily attributed to its high content of nitrate since it is converted
      to nitric oxide independent of the vascular endothelium via the enterosalivary
      nitrate-nitrite-nitric oxide pathway. However, red beetroot juice contains a number of other
      potentially beneficial bioactive compounds and few studies have aimed to determine whether
      these compounds work independently, additively, or synergistically in exerting these effects.
      Given the findings of previously conducted research in the broad area of red beetroot juice
      consumption and human health, it can be suggested that: 1) acute red beetroot juice
      consumption may prevent or attenuate the adverse postprandial responses to consuming a
      high-fat meal in individuals with exaggerated responses; and 2) chronic consumption of red
      beetroot may improve underlying factors contributing to these exaggerated responses.
      Accordingly, this project aims to: 1) investigate the efficacy of acute and chronic whole red
      beetroot juice consumption compared with its bioactive components in attenuating postprandial
      vascular endothelial dysfunction and adverse cardiometabolic responses to a high-fat meal;
      and 2) to gain insight into the underlying mechanisms responsible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 4-period, 4-week crossover pilot
      clinical trial consisting of 2 postprandial tests for each period. Overweight or obese
      postmenopausal women and men aged 40 to 65 will be recruited from the greater Fort Collins,
      CO area. After telephone prescreening, participants will report to the study site for their
      first visit (Screening) where they will receive verbal and written explanation of the
      project, provide informed consent, followed by screening assessments. Qualified participants
      will be scheduled for a baseline visit and randomly assigned to their respective treatments.
      On the second visit (Baseline) following an overnight fast, anthropometrics and blood
      pressure will be measured and diet and physical activity records will be collected. Subjects
      will ingest their respective treatment 10 min prior to consuming the high-fat test meal.
      Various assessments will be performed and samples collected prior to and up to 4 hours
      post-meal consumption. At the third visit (Final), all assessments and sample collections
      will be repeated at the same time points but 24 hours after consuming the last dose of their
      respective treatments to test chronic rather than acute effects. Subjects will undergo a
      4-week washout period before crossing over to the next treatment period. This will be
      repeated for all 4 treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular endothelial function</measure>
    <time_frame>0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Vascular endothelial function will be assessed using reactive hyperemia index (EndoPAT) 0 and 4 hours post-meal consumption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood glucose, insulin, C-peptide, and indices of insulin sensitivity and resistance</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Blood glucose, insulin, and C-peptide will be measured by biochemical analysis at 0 and 1, 2, and 4 hours post-meal consumption and indices of insulin sensitivity and resistance will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids and lipoproteins</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Blood lipids and lipoproteins will be measured by biochemical analysis at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period</time_frame>
    <description>Peripheral and central blood pressure measured by an automatic sphygmomanometer and SphygmoCor at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Heart rate will be measured by an automatic sphygmomanometer and SphygmoCor at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Heart rate variability will be assessed (EndoPAT) at 0 and 4 hours post-meal consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Pre-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Arterial stiffness will be assessed as carotid-femoral pulse wave velocity and augmentation index (using SphygmCor and EndoPAT) at baseline and 1 month periods (pre-meal consumption).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric oxide biomarkers</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Nitric oxide metabolites and molecules involved in nitric oxide production and bioavailability will be evaluated in saliva, blood, peripheral blood mononuclear cells, and biopsied venous endothelial cells at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress biomarkers</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Biomarkers of oxidative stress will be evaluating in blood, peripheral blood mononuclear cells, and biopsied venous endothelial cells at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory biomarkers</measure>
    <time_frame>0 and 1, 2, and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Biomarkers of inflammation will be evaluating in blood, peripheral blood mononuclear cells, and biopsied venous endothelial cells at 0 and 1, 2, and 4 hours post-meal consumption.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood polyphenols and polyphenol metabolites</measure>
    <time_frame>0 and 4 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Blood polyphenols and metabolites will be measured by liquid and gas chromotography-mass spectrometry (LC/MS and GC/MS) at 0 and 4 hours post-meal consumption.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary polyphenols and polyphenol metabolites</measure>
    <time_frame>0 and 24 hours post-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>Urinary polyphenols and metabolites will be measured by liquid and gas chromotography-mass spectrometry (LC/MS and GC/MS) at 0 and 4 hours post-meal consumption.</description>
  </other_outcome>
  <other_outcome>
    <measure>Oral and gut microbiome</measure>
    <time_frame>Pre-meal consumption at baseline and 1 month for each treatment period.</time_frame>
    <description>The role of the oral and gut microbiome in efficacy of treatments at baseline and over time will be evaluated.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Aging</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>70 mL red beetroot juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70 mL red beetroot juice naturally containing 300 mg nitrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 mL placebo drink plus potassium nitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 mL red beetroot juice without nitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 mL red beetroot juice per day without nitrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 mL placebo drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>70 mL red beetroot juice</intervention_name>
    <description>1x daily intake of 70 mL red beetroot juice</description>
    <arm_group_label>70 mL red beetroot juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>70 mL red beetroot juice without nitrate</intervention_name>
    <description>1x daily intake of 70 mL red beetroot juice without nitrate</description>
    <arm_group_label>70 mL red beetroot juice without nitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>70 mL placebo drink plus potassium nitrate</intervention_name>
    <description>1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)</description>
    <arm_group_label>70 mL placebo drink plus potassium nitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>70 mL placebo drink</intervention_name>
    <description>1x daily intake of 70 mL placebo control drink</description>
    <arm_group_label>70 mL placebo drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women and men

          -  BMI between 25 and 40 kg/m2

        Exclusion Criteria:

          -  Hypertension, cardiovascular disease, diabetes, cancer, or kidney, liver, or
             pancreatic disease

          -  Individuals taking gastroesophageal reflux, antihypertensive, hypoglycemic,
             lipid-lowering, hormone replacement, erectile dysfunction medications or nitrates

          -  Participating in a weight loss program or actively trying to lose weight

          -  Heavy smokers (â‰¥ 20 cigarettes/d)

          -  Heavy drinkers (&gt; 12 drinks/wk)

          -  Allergy to meals/treatments

          -  Consuming &gt; 2 servings red beetroot or beetroot juice/wk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah A Johnson, PhD, RDN</last_name>
    <phone>970-491-3807</phone>
    <email>Sarah.Johnson@colostate.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Food Science and Human Nutrition, Colorado State University</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523-1571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah A Johnson, PhD, RDN</last_name>
      <phone>970-491-3807</phone>
      <email>Sarah.Johnson@colostate.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah A Johnson, PhD, RDN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado State University</investigator_affiliation>
    <investigator_full_name>Sarah Johnson</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Red beetroot</keyword>
  <keyword>Dietary Nitrate</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>High-Fat Meal</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <keyword>Aging</keyword>
  <keyword>Cardiometabolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

